News

Under the deal, the partners will assess Array's MEK inhibitor binimetinib in combination with Pfizer's investigational PARP inhibitor talazoparib and human anti-PD-L1 IgG1 monoclonal antibody avelumab. They will evaluate

The collaboration is part of Boehringer Ingelheim's Research Beyond Borders (RBB) initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new

This sale supports Impax's operational and cost improvement plans to streamline operations and reduce costs. Under the terms of the agreement, Bora will purchase all of the issued

The investigational adeno-associated viral (AAV) vector gene therapy has been approved as a one-time gene therapy for confirmed Biallelic RPE65 mutation-associated retinal dystrophy. Patients having RPE65-mediated inherited retinal disease

Patisiran was previously granted accelerated assessment by the EMA, potentially reducing the Agency’s evaluation time from 210 to 150 days. “The MAA submission for patisiran represents another important

Regeneron and ISA will jointly fund and conduct clinical trials of the combination treatment in cervical cancer and head-and-neck cancer. Expression of HPV oncoproteins contributes to the development

Vraylar (cariprazine) is an oral and once daily atypical antipsychotic secured approval for the acute treatment of adult patients with manic or mixed episodes associated with bipolar I

Published in draft guidance, the enforcement priorities are expected to keep a check on certain homeopathic drugs that can be harmful and have no proven medical benefits. The

Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate